Program Evaluation
*
LowBelow AverageAverageAbove AverageHigh
E. David Crawford, MD
Steven E. Finkelstein, MD
Daniel P. Petrylak, MD
Matt T. Rosenberg, MD
Format
Program Materials
Level of Interaction
*
Strongly DisagreeDisagreeNeutralAgreeStrongly Agree
Describe the mechanisms, safety profiles and indications of newly-approved agents for the treatment of metastatic castration-resistant prostate cancer.
Determine optimal strategies for the sequencing and combination of therapeutic agents in the treatment of metastatic castration-resistant prostate cancer.
Assess the role of predictive and prognostic biomarkers in the treatment of metastatic castration-resistant prostate cancer.
*
Strongly DisagreeDisagreeNeutralAgreeStrongly Agree
This activity met my educational needs, expectations, and objectives
This activity was relevant to my practice
I feel confident treating patients in my practice based on this activity
This activity rates highly in comparison with other CME activities in which I have participated in the last 12 months
There is a continuing need for education on this topic
The presentation was scientifically sound and free of commercial bias or influence
*
*
*
*
*